(opens in a new window)

Luis J. Montaner, MD

Wistar Institute Professor of Medicine (Infectious Diseases)

Department: Medicine
Division: Infectious Diseases


Graduate Group Affiliations


Contact Information

The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Office: 215-898-9143
Lab Phone: 215-898-3934
Email: montaner@wistar.org


I3H Keywords

  • Innate and Adaptive Immunity to Pathogens
  • Tumor Microenvironment

Publications

Pubmed Link


Links


Education

  • B.S.
    Kansas State University, 1989
  • D.V.M. (Veterinary Medicine)
    Kansas State University, 1991
  • M.Sc. (Veterinary Pathology)
    Kansas State University, 1991
  • D.Phil. (Experimental Pathology)
    University of Oxford, 1995

Post-Graduate Training

  • Research Internships, New England Regional Primate Research Center
    Harvard School of Medicine, 1990 - 1990
  • DPhil Studentship, Sir William Dunn School of Pathology
    University of Oxford, 1991 - 1994
  • Assistant Electron Microscopist
    Department of Veterinary Pathology, Kansas State University, 1986 - 1989

Description of Research Expertise

Research Interests
Our goal is to develop a better understanding of HIV-1 immunopathogenesis and new immune-based strategies of anti-HIV therapy that are better tolerated and more sustainable for patient populations than the life-long use of antiretroviral therapy.

Research Description
Introduction

The Montaner laboratory is investigating mechanisms of disease in HIV-1 infection and novel approaches to augment immune function by combining virological and immune-based research on patient-derived material as well as by using laboratory models of virus infection. The work is focused on 1) regulation of innate immunity, 2) identifying new mechanisms of immunodeficiency and discovering new approaches to reverse them, 3) exploring new therapy management practices, and 4) understanding the relationship between immune antiviral responses and control of HIV-1 infection.

Current Research Activities and Interests

Innate Immunity & HIV-1 Infection: Dendritic cells & Natural Killer Cells Direct or indirect interactions of viral particles with innate and specific adaptive immunity effector cells affects the cross talk between antigen presenting cells (APCs), NK cells and the antigen specific T and B-lymphocytes, and may contribute to regulate HIV disease progression. Specifically, we are pursuing analysis of the effects of HIV infection in macrophages, dendritic cells and Natural Killer cells.

A relationship between levels of HIV replication and innate cell function is supported by our preliminary data on DC and NK subset changes and viral replication in HIV-infected individuals showing an impairment of NK cell responses, APC endocytic uptake, differential expression of cell surface molecules associated with APC function, increased APC apoptosis, decreased IL-12 secretion, decreased IFN-? secretion and a loss of plasmacytoid dendritic cells (PDCs) and myeloid dendritic cells (MDCs) in PBMC. Based on these observations and the observed effects of antiretroviral therapy on DC and NK cell subsets, the inverse correlation between viral load and DC subsets in untreated HIV positive subjects and our observations of augmented NK lytic activity by activated DC, we are addressing longitudinal analysis and mechanistic experiments on DC/HIV interactions to test the hypothesis that HAART-mediated viral suppression restores mature NK and DC subsets necessary to activate innate mechanisms of antiviral control through lysis of infected cells. The long-term goal of this area of focus is to define the contribution of two major components of the innate immune system (accessory and Natural Killer cells) in controlling HIV replication thereby modifying disease progression. The short-term goal of our effort is to address the consequences of immune reconstitution on innate immunity following antiretroviral therapy, with particular emphasis on correlates of DC and NK cell functions and the consequences of HIV interactions with DC subsets. While adaptive HIV-specific immune responses continue to be an area of active investigation in AIDS research, the potential contribution of innate immune response, such as the relationship between DC subsets, disease progression and its consequences on other innate functions such as NK function remains largely unexplored in HAART settings. This study represents a hypothesis-driven collaborative effort by The Wistar Institute, the Infectious Disease Division of the University of Pennsylvania Hospital, Philadelphia FIGHT, Schering-Plough, Becton Dickinson, The Women's Interagency Study Cohort and the Multiple AIDS Cohort Study (MACS).

Description of ITMAT Expertise

Working closely with exposed or infected adult and pediatric HIV/AIDS patient populations in the Philadelphia region, Puerto Rico, Mexico and South Africa The Montaner laboratory is investigating mechanisms of disease and/or coinfections in HIV-1 infected and novel approaches to augment immune function. The work is focused on 1) regulation of innate immunity, 2) identifying new mechanisms of immunodeficiency and discovering new approaches to reverse them, 3) exploring new therapy management practices in coinfection settings, and 4) understanding the relationship between immune antiviral responses and control of disease.

Selected Publications

  • Gunst, J., Gohil, J., Li, J., Bosch, R., White, A., Seamon, C., Chun, T.-W., Mothe, B., Gittens, K., Praiss, L., De Scheerder, M.-A., Vandekerckhove, L., Escandón, K., thorkelson, A., Schacker, T., SenGupta, D., Brander, C., Papasavvas, E., Montaner, L.J., Martinez-Picado, J., Calin, R., Castagna, A., Muccini, C., Jong, W., Leal, L., Garcia, F., Gruters, R., Tipoe, T., Frater, J., Sogaard O., Fidler, S. : Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: An individual data-based meta-analysis of 24 prospective studies Nature Communications Jan 2025
  • Moskovjevic, M., Dragoni, F., Board, N.L., Wu, F., Lai, J., Zhang, H., White, J., Hoh, R., Lynn, K., Tebas, P., Mounzer, K., Deeks, S.G., Montaner, L.J., Siliciano, J.D., Siliciano, R.F., Simonetti, F.R. : Cognate antigen engagement induces HIV-1 expression in latently infected CD4+ T cells from people on long-term antiretroviral therapy Immunity Nov 2024
  • Emade Nkwelle, C., Babiaka, S.B., Metuge, C.S., Liang, K., Stephens, U., Esemu, S.N., Zuzga, D.S., Shuda McGuire, K., Montaner, L.J., Ndip, R.N., Tietjen, I., Ntie-Kang, F. : Croton oligandrus Pierre & Hutch (Euphorbiaceae) Extracts and Isolated Compounds Reverse HIV-1 Latency Journal of Experimental Pharmacology Nov 2024
  • Meanley, S., Carter, W., Short, W.B., Metzger, D.S., Onorato, A., Montaner, L.J., Dubé, K. : HIV Clinical Providers' Awareness, Attitudes, and Willingness to Support Patient Outreach Efforts for HIV Cure-Directed Research in Philadelphia, United States Open Forum Infectious Diseases Nov 2024
  • Poli, A.N.R., Tietjen, I., Nandwana, N.K., Cassel, J., Messick, T.E., Register, E.T., Keeney, F., Rajaiah, R., Verma, A.K., Pandey, K., Acharya, A., Byrareddy, S.N., Montaner, L.J., Salvino, J.M. : Design of novel and highly selective SARS-CoV-2 main protease inhibitors. Antimicrobial Agents and Chemotherapy Oct 2024
  • Rajaiah, R., Pandey, K., Achrya, A., Ambikan, A., Kumar, N., Guda, R., Avedissian, S.N., Montaner, L.J., Cohen, S.M., Neogi, U., Byareddy, S.N. : Differential immunometabolic responses to Delta and Omicron SARS-CoV-2 variants in golden Syrian hamsters iScience Aug 2024
  • Namba-Nzanguim, C.T., Simoben, C.V., Bekono, B.D., Tietjen, I., Cassel, J., Salvino, J.M., Montaner, L.J., Davis, R.A., Ntie-Kang, F. : Investigation of some plant stilbenoids and their fragments for the identification of inhibitors of SARS-CoV2 viral spike/ACE2 protein binding The Microbe Jun 2024
  • Matos-Hernández, M., Samples, R., Dyer, G., Casimir Montan, V., Morales-Colón, C., Salvino, J., Montaner, L.J., Cassel, J., Messick, T., Tietjen, I., Caro-Diaz, E. : Metabolomic Analysis and Antiviral Screening of a Marine Algae Library Yield Jobosic Acid (2,5-Dimethyltetradecanoic Acid) as a Selective Inhibitor of SARS-CoV-2 Journal of Natural Products Jun 2024
  • Shayo, M.J., Samwel, B., Shadrack, D.M., Cassel, J., Salvino, J.M., Montaner, L.J., Deogratias, G., Tietjen, I., Kiruri, L., Hilonga, S., Innocent, E. : Drug repositioning identifies salvinorin A and deacetylgedunin (DCG) enriched plant extracts as novel inhibitors of Mpro, RBD-ACE2 and TMPRRS2 proteins RSC Advances Jun 2024
  • Shellenberger, B.M., Basile, O.N., Cassel, J., Olsen, M.R., Salvino, J.M., Montaner, L.J., Tietjen, I., Henry, G.E. : Synthesis, SARS-CoV-2 main protease inhibition, molecular docking and in silico ADME studies of furanochromene-quinoline hydrazone derivatives Bioorganic & Medicinal Chemistry Letters Apr 2024